Antti Nurmi, PhD, MSc
Managing Director, Discovery Services
Kuopio, Finland
"Tackling neurodegenerative disorders requires a more in-depth understanding of the mechanisms behind the diseases. Drug developers are partnering with leading service providers to explore new routes. We are implementing clinically relevant structural and functional imaging in animal models to support translational drug research for CNS disorders."
Omar Aziz, PhD
Senior Director, Discovery Services
South San Francisco, CA
“High attrition rates make CNS drug discovery challenging, but with the right models and tools, it doesn’t have to be. Collecting rich data early on allows us to move the best molecules forward through development. For example, we now have the capability to bioanalyze engineered antibodies, cellular and gene therapies, to profile compounds and optimize delivery to the brain.”
Jackie MacRitchie, PhD
Senior Managing Director Discovery
Saffron Waldon, UK
“An understanding of the neurological disease, at the molecular level and through to how it impacts the patient, is key to developing stem cell derived neurons, performing high throughput screening assays and designing novel molecules.”
Holden Janssens, PhD
Director, In Vivo Pharmacology
South San Francisco, CA
Diana Miszczuk
Assoc Director CNS Pharmacology
Helsinki, Southern Finland
Gunnar Flik, PhD
Site Director, Operations
Groningen, The Netherlands
David Fischer, PhD
Executive Director,
Scientific Advisory Services
Saffron Waldon, UK
Toni Ahtoniemi, PhD
Associate Director,
Client Services
Kuopio, Finland